conclusions alendronate may be considered a therapeutic option for improving the bone formation process and reducing resorption in different bone grafting procedures. further detailed studies should focus on dosage and time-dependent effects of alendronate on bone remodeling. results at 6 weeks, the bone area was significantly larger in the xenograft-alendronate group (33.0% ± 5.0%) than in the...

conclusions our study demonstrates positive results (preservation or regeneration of bone) using prp in treatment of bronj. although prp may enhance osseous regeneration, long-term follow-ups are required to confirm its benefits. background bisphosphonate-related osteonecrosis of the jaws (bronj) is a well-known challenging entity warranting management. platelet-rich plasma (prp) plays an impor...

i ntroduction: bisphosphonates are  widely used  for  various bone  diseases including osteoporosis and bone tumors. one of the complications associated with these pharmaceutical agents is bisphosphonate-related osteonecrosis of the jaw. this condition may be triggered by placement of dental implants. in turn,  osteonecrosis  of  the  jaw  may  cause  failure  in  osseointegration  of implants....

Background: Osteoporosis is a common condition among the elderly population, and is associated with an increased risk of fracture. One of the most common fragility fractures involve the distal radius, and are associated with risk of subsequent fragility fracture. Early treatment with bisphosphonates has been suggested to decrease the population hip fracture burden. However, there have been no p...

An open-label study conducted in community centers assessed the safety of zoledronic acid 4 mg intravenously over 15 minutes every 3-4 weeks as treatment of bone metastases in patients with multiple myeloma, breast cancer, or prostate cancer with and without previous bisphosphonate exposure. Adverse events (AEs), pain, and quality-of-life (QOL) scores were recorded, and serum creatinine (SCr) l...

PURPOSE The aim of this cross-sectional health care study (use of bisphosphonates in primary tumors of the mammae, EBisMa) is to determine how often bisphosphonate medication is used in patients with non-metastatic primary breast cancer treatment, but who do not suffer from osteoporosis. Furthermore, we describe patients' characteristics and the most frequently used type of bisphosphonate in ad...

BACKGROUND The purpose of this study was to estimate the positive predictive value (PPV) of the coding for bisphosphonate treatment in selected cancer patients from the Danish National Patient Registry (DNPR). METHODS Through the DNPR, we identified all patients with recorded cancer of the breast, prostate, lung, kidney, and with multiple myeloma. We restricted the study sample to patients wi...

BACKGROUND Atypical femoral fracture (AFF) has been high-lightened, because it was associated with the long-term use of bisphosphonate. Comparing western countries, the incidence rate of AFF was unclear in East Asian patients. Our purposes were to estimate the incidence rate of radiologically defined AFF in Korea, and to determine the association between occurrence of AFF and long-term use of b...

BACKGROUND Epidemiology studies suggest that oral bisphosphonate may increase the risk of esophageal cancer. The present study aimed to investigate the association between exposure of oral bisphosphonate and risk of esophageal cancer. METHODS Using the nationwide medical claim database in South Korea, 2,167,955 subjects, who initiated osteoporosis treatment (oral bisphosphonate, intravenous b...

CONTEXT An expert opinion perspective on why osteoporosis is underdiagnosed and undertreated. OBJECTIVE To highlight the potential reasons for why osteoporosis is undertreated. DESIGN Literature review from PubMed, Plos One, and Science Direct search engines from 1900-2015 under terms: sub-trochanteric and atypical femur fractures, bisphosphonate clinical trial and bisphosphonate review art...